Deutsche Bank Ag\ Viking Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 6,427 shares of VKTX stock, worth $218,967. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,427

Previous 21,711 70.4%

Holding current value

$218,967

Previous $1.37 Million 81.22%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$38.28 - $78.03 $585,071 - $1.19 Million	-15,284 Reduced 70.4%	6,427 $258,000
Q3 2024 Nov 13, 2024	SELL	$49.84 - $70.47 $5.13 Million - $7.26 Million	-102,983 Reduced 82.59%	21,711 $1.37 Million
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $2.21 Million - $3.74 Million	-46,650 Reduced 27.23%	124,694 $6.61 Million
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $12 Million - $65 Million	-688,347 Reduced 80.07%	171,344 $14.1 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $5 Million - $10.6 Million	541,403 Added 170.1%	859,691 $16 Million
Q3 2023 Nov 09, 2023	BUY	$10.92 - $16.0 $410,035 - $600,784	37,549 Added 13.38%	318,288 $3.52 Million
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $616,423 - $1.03 Million	41,538 Added 17.37%	280,739 $4.55 Million
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $11,845 - $25,405	-1,466 Reduced 0.61%	239,201 $3.98 Million
Q2 2022 Aug 11, 2022	SELL	$2.11 - $3.15 $78,344 - $116,959	-37,130 Reduced 13.37%	240,667 $696,000
Q1 2022 May 13, 2022	SELL	$3.0 - $4.88 $13,254 - $21,559	-4,418 Reduced 1.57%	277,797 $833,000
Q4 2021 Feb 11, 2022	BUY	$4.6 - $6.72 $5,800 - $8,473	1,261 Added 0.45%	282,215 $1.3 Million
Q3 2021 Nov 04, 2021	SELL	$5.58 - $7.04 $14,982 - $18,902	-2,685 Reduced 0.95%	280,954 $1.76 Million
Q2 2021 Aug 11, 2021	SELL	$5.19 - $6.73 $7,795 - $10,108	-1,502 Reduced 0.53%	283,639 $1.7 Million
Q1 2021 May 13, 2021	BUY	$5.74 - $9.67 $351,253 - $591,745	61,194 Added 27.33%	285,141 $1.8 Million
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $66,658 - $84,391	12,577 Added 5.95%	223,947 $1.26 Million
Q3 2020 Nov 12, 2020	SELL	$5.73 - $8.11 $7,145 - $10,113	-1,247 Reduced 0.59%	211,370 $1.23 Million
Q2 2020 Aug 13, 2020	BUY	$4.35 - $8.08 $191,856 - $356,368	44,105 Added 26.17%	212,617 $1.53 Million
Q1 2020 May 14, 2020	SELL	$3.45 - $7.95 $4,802 - $11,066	-1,392 Reduced 0.82%	168,512 $788,000
Q4 2019 Feb 14, 2020	BUY	$6.38 - $8.73 $30,604 - $41,877	4,797 Added 2.91%	169,904 $1.36 Million
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $20,291 - $26,642	-3,098 Reduced 1.84%	165,107 $1.14 Million
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $27,243 - $37,757	-3,552 Reduced 2.07%	168,205 $1.39 Million
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $4,980 - $6,530	-657 Reduced 0.38%	171,757 $1.71 Million
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $2.98 Million - $6.75 Million	-416,663 Reduced 70.73%	172,414 $1.32 Million
Q3 2018 Dec 21, 2021	BUY	$9.7 - $19.65 $3.23 Million - $6.54 Million	333,034 Added 130.07%	589,077 $10.3 Million
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $386,603 - $783,170	39,856 Added 18.44%	256,043 $4.46 Million
Q2 2018 Apr 21, 2020	BUY	$3.88 - $12.74 $54,836 - $180,054	14,133 Added 6.99%	216,187 $2.05 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $781,350 - $2.57 Million	201,379 Added 29833.93%	202,054 $1.92 Million
Q1 2018 May 15, 2018	SELL	$4.11 - $6.93 $6,678 - $11,261	-1,625 Reduced 70.65%	675 $2,000
Q4 2017 Feb 14, 2018	BUY	$1.74 - $4.34 $4,002 - $9,982	2,300	2,300 $9,000

Others Institutions Holding VKTX

# of Institutions

466

Shares Held

65.8M

Call Options Held

5.84M

Put Options Held

3.76M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.61B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account